Skip to content

Immix Biopharma, Inc. IMMX Common Stock, Shares, Outstanding

Common Stock, Shares, Outstanding at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
Precigen logo
PrecigenPGEN
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s common stock, shares, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s common stock, shares, outstanding?
Immix Biopharma, Inc. (IMMX) reported common stock, shares, outstanding of $53.01M in Q1 2026.
How has Immix Biopharma, Inc.'s common stock, shares, outstanding changed year-over-year?
Immix Biopharma, Inc.'s common stock, shares, outstanding increased by 90.3% year-over-year, from $27.85M to $53.01M.
What is the long-term trend for Immix Biopharma, Inc.'s common stock, shares, outstanding?
Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s common stock, shares, outstanding has grown at a 73.4% compound annual growth rate (CAGR), from $3.38M to $52.95M.